# Merck & Co. timeline

entity: /record/merck.md  
id: ent_merck  

Merck & Co.'s timeline holds 503 claims from 1994 to 2026: 492 money & deals, 11 other. 8 are undated. The latest took effect on October 31, 2026.

Kinds: People 0 (/timelines/merck.md?kind=people) · Money & deals 492 (/timelines/merck.md?kind=money) · Products 0 (/timelines/merck.md?kind=products) · Models 0 (/timelines/merck.md?kind=models) · Other 11 (/timelines/merck.md?kind=other)  
Format: date | kind | predicate | value | status | claim.

## 1994

- 1994-12-29 to 2009-10-29 | other | registrant_name | SCHERING PLOUGH CORP | superseded | [clm_B41895454D67](/claim/clm_B41895454D67.md)

## 2006

- 2006-12-31 to 2007-12-31 | money | cash_and_equivalents | 5,914,700,000 United States dollar | superseded | [clm_1F1D245F44D6](/claim/clm_1F1D245F44D6.md)
- 2006-12-31 to 2007-12-31 | money | total_equity | 19,965,800,000 United States dollar | superseded | [clm_4496266C128D](/claim/clm_4496266C128D.md)

## 2007

- 2007-12-31 to 2008-06-30 | money | cash_and_equivalents | 5,336,100,000 United States dollar | superseded | [clm_F2BA78F20E9F](/claim/clm_F2BA78F20E9F.md)
- 2007-12-31 to 2008-12-31 | money | net_income | 3,275,400,000 United States dollar | superseded | [clm_EF9A8E802FB5](/claim/clm_EF9A8E802FB5.md)
- 2007-12-31 to 2008-12-31 | money | research_and_development | 4,882,800,000 United States dollar | superseded | [clm_E830E102F96E](/claim/clm_E830E102F96E.md)
- 2007-12-31 to 2008-12-31 | money | revenue | 24,197,700,000 United States dollar | superseded | [clm_5DBE0DD30DAD](/claim/clm_5DBE0DD30DAD.md)
- 2007-12-31 to 2008-12-31 | money | total_equity | 20,591,400,000 United States dollar | superseded | [clm_5165C273DFBC](/claim/clm_5165C273DFBC.md)

## 2008

- 2008-06-30 to 2008-09-30 | money | cash_and_equivalents | 2,705,000,000 United States dollar | superseded | [clm_39FFF425906C](/claim/clm_39FFF425906C.md)
- 2008-06-30 to 2008-09-30 | money | quarterly_net_income | 462,000,000 United States dollar | superseded | [clm_10D2DE05595D](/claim/clm_10D2DE05595D.md)
- 2008-06-30 to 2008-09-30 | money | quarterly_research_and_development | 906,000,000 United States dollar | superseded | [clm_A11256338AE1](/claim/clm_A11256338AE1.md)
- 2008-06-30 to 2008-09-30 | money | quarterly_revenue | 4,921,000,000 United States dollar | superseded | [clm_66C40BC5AB58](/claim/clm_66C40BC5AB58.md)
- 2008-09-30 to 2008-12-31 | money | cash_and_equivalents | 3,159,000,000 United States dollar | superseded | [clm_B27C1DE2C9B9](/claim/clm_B27C1DE2C9B9.md)
- 2008-09-30 to 2009-03-31 | money | quarterly_net_income | 614,000,000 United States dollar | superseded | [clm_BEEB13A3FCFF](/claim/clm_BEEB13A3FCFF.md)
- 2008-09-30 to 2009-03-31 | money | quarterly_research_and_development | 893,000,000 United States dollar | superseded | [clm_0012D0EF4581](/claim/clm_0012D0EF4581.md)
- 2008-09-30 to 2009-03-31 | money | quarterly_revenue | 4,576,000,000 United States dollar | superseded | [clm_2C246AABD63D](/claim/clm_2C246AABD63D.md)
- 2008-12-31 to 2009-03-31 | money | cash_and_equivalents | 4,368,300,000 United States dollar | superseded | [clm_5C437D324996](/claim/clm_5C437D324996.md)
- 2008-12-31 to 2009-12-31 | money | net_income | 7,808,400,000 United States dollar | superseded | [clm_AC1DCB2822D2](/claim/clm_AC1DCB2822D2.md)
- 2008-12-31 to 2009-12-31 | money | research_and_development | 4,805,300,000 United States dollar | superseded | [clm_AD7D2ACA144B](/claim/clm_AD7D2ACA144B.md)
- 2008-12-31 to 2009-12-31 | money | revenue | 23,850,300,000 United States dollar | superseded | [clm_6AB36311B283](/claim/clm_6AB36311B283.md)
- 2008-12-31 to 2009-06-30 | money | total_assets | 47,195,700,000 United States dollar | superseded | [clm_5FD9363AA3ED](/claim/clm_5FD9363AA3ED.md)
- 2008-12-31 to 2009-06-30 | money | total_equity | 18,758,300,000 United States dollar | superseded | [clm_0C23DECD923D](/claim/clm_0C23DECD923D.md)

## 2009

- 2009-03-31 to 2009-06-30 | money | cash_and_equivalents | 6,017,100,000 United States dollar | superseded | [clm_4EDF0B1989AE](/claim/clm_4EDF0B1989AE.md)
- 2009-03-31 to 2009-06-30 | money | quarterly_net_income | 1,425,000,000 United States dollar | superseded | [clm_AA38C432CDB7](/claim/clm_AA38C432CDB7.md)
- 2009-03-31 to 2009-06-30 | money | quarterly_research_and_development | 1,224,200,000 United States dollar | superseded | [clm_E816BE82558E](/claim/clm_E816BE82558E.md)
- 2009-03-31 to 2009-06-30 | money | quarterly_revenue | 5,385,200,000 United States dollar | superseded | [clm_C8A4E67B495C](/claim/clm_C8A4E67B495C.md)
- 2009-04-27 | other | x_username | merck | unverified | [clm_6BB2CF8F4BA7](/claim/clm_6BB2CF8F4BA7.md)
- 2009-06-30 to 2009-09-30 | money | cash_and_equivalents | 2,989,000,000 United States dollar | superseded | [clm_2285A0A34C73](/claim/clm_2285A0A34C73.md)
- 2009-06-30 to 2009-09-30 | money | quarterly_net_income | 671,000,000 United States dollar | superseded | [clm_048EC2C80B3F](/claim/clm_048EC2C80B3F.md)
- 2009-06-30 to 2009-09-30 | money | quarterly_research_and_development | 863,000,000 United States dollar | superseded | [clm_C47CB8AEE9D1](/claim/clm_C47CB8AEE9D1.md)
- 2009-06-30 to 2009-09-30 | money | quarterly_revenue | 5,899,900,000 United States dollar | superseded | [clm_3CA7D1DAEFB3](/claim/clm_3CA7D1DAEFB3.md)
- 2009-06-30 to 2009-09-30 | money | shares_outstanding | 0 shares | superseded | [clm_6D871C86295C](/claim/clm_6D871C86295C.md)
- 2009-06-30 to 2009-09-30 | money | total_assets | 29,545,000,000 United States dollar | superseded | [clm_3184EF4E173F](/claim/clm_3184EF4E173F.md)
- 2009-06-30 to 2009-09-30 | money | total_equity | 12,035,000,000 United States dollar | superseded | [clm_133163071D45](/claim/clm_133163071D45.md)
- 2009-09-30 to 2009-12-31 | money | cash_and_equivalents | 4,312,000,000 United States dollar | superseded | [clm_4D5FB6156251](/claim/clm_4D5FB6156251.md)
- 2009-09-30 to 2010-03-31 | money | quarterly_net_income | 515,000,000 United States dollar | superseded | [clm_AAC4D7B22371](/claim/clm_AAC4D7B22371.md)
- 2009-09-30 to 2010-03-31 | money | quarterly_research_and_development | 913,000,000 United States dollar | superseded | [clm_9F8BAD62BE47](/claim/clm_9F8BAD62BE47.md)
- 2009-09-30 to 2010-03-31 | money | quarterly_revenue | 6,049,700,000 United States dollar | superseded | [clm_0FE78409134C](/claim/clm_0FE78409134C.md)
- 2009-09-30 to 2010-01-29 | money | shares_outstanding | 1,639,151,392 shares | superseded | [clm_5904E31120BB](/claim/clm_5904E31120BB.md)
- 2009-09-30 to 2009-12-31 | money | total_assets | 30,547,000,000 United States dollar | superseded | [clm_5D1DFB0B7A44](/claim/clm_5D1DFB0B7A44.md)
- 2009-09-30 to 2009-12-31 | money | total_equity | 12,900,000,000 United States dollar | superseded | [clm_43B087FEC347](/claim/clm_43B087FEC347.md)
- 2009-11-04 | other | registrant_name | Merck & Co., Inc. | valid | [clm_57A2834F3A81](/claim/clm_57A2834F3A81.md)
- 2009-12-31 to 2010-03-31 | money | cash_and_equivalents | 9,311,400,000 United States dollar | superseded | [clm_47722B45F6C8](/claim/clm_47722B45F6C8.md)
- 2009-12-31 to 2010-12-31 | money | net_income | 12,901,300,000 United States dollar | superseded | [clm_7347BADF2C70](/claim/clm_7347BADF2C70.md)
- 2009-12-31 to 2010-12-31 | money | research_and_development | 5,845,000,000 United States dollar | superseded | [clm_2398410359B8](/claim/clm_2398410359B8.md)
- 2009-12-31 to 2010-12-31 | money | revenue | 27,428,300,000 United States dollar | superseded | [clm_096391AC4DDE](/claim/clm_096391AC4DDE.md)
- 2009-12-31 to 2010-03-31 | money | total_assets | 112,089,700,000 United States dollar | superseded | [clm_FEC4D5849978](/claim/clm_FEC4D5849978.md)
- 2009-12-31 to 2010-03-31 | money | total_equity | 59,058,000,000 United States dollar | superseded | [clm_ACC2D700771A](/claim/clm_ACC2D700771A.md)

## 2010

- 2010-01-29 to 2010-04-30 | money | shares_outstanding | 3,115,317,260 shares | superseded | [clm_CFB9418D7005](/claim/clm_CFB9418D7005.md)
- 2010-03-31 to 2010-06-30 | money | cash_and_equivalents | 8,236,000,000 United States dollar | superseded | [clm_6A4764C9BAB4](/claim/clm_6A4764C9BAB4.md)
- 2010-03-31 to 2010-06-30 | money | quarterly_net_income | 298,800,000 United States dollar | superseded | [clm_D1947D5F192E](/claim/clm_D1947D5F192E.md)
- 2010-03-31 to 2010-06-30 | money | quarterly_research_and_development | 2,026,700,000 United States dollar | superseded | [clm_49575E9AC377](/claim/clm_49575E9AC377.md)
- 2010-03-31 to 2010-06-30 | money | quarterly_revenue | 11,422,200,000 United States dollar | superseded | [clm_A4F0D35F6BFE](/claim/clm_A4F0D35F6BFE.md)
- 2010-03-31 to 2010-06-30 | money | total_assets | 111,593,800,000 United States dollar | superseded | [clm_CEF5E014EF03](/claim/clm_CEF5E014EF03.md)
- 2010-03-31 to 2010-06-30 | money | total_equity | 57,878,100,000 United States dollar | superseded | [clm_C4DA1A536A80](/claim/clm_C4DA1A536A80.md)
- 2010-04-30 to 2010-07-30 | money | shares_outstanding | 3,118,252,244 shares | superseded | [clm_6BFEF753A9AF](/claim/clm_6BFEF753A9AF.md)
- 2010-06-30 to 2010-09-30 | money | cash_and_equivalents | 8,665,600,000 United States dollar | superseded | [clm_0BF16A111DB1](/claim/clm_0BF16A111DB1.md)
- 2010-06-30 to 2010-09-30 | money | quarterly_net_income | 752,400,000 United States dollar | superseded | [clm_87DCBE668D46](/claim/clm_87DCBE668D46.md)
- 2010-06-30 to 2010-09-30 | money | quarterly_research_and_development | 2,150,900,000 United States dollar | superseded | [clm_8425BCAEBDE4](/claim/clm_8425BCAEBDE4.md)
- 2010-06-30 to 2010-09-30 | money | quarterly_revenue | 11,346,300,000 United States dollar | superseded | [clm_D746F14C7469](/claim/clm_D746F14C7469.md)
- 2010-06-30 to 2010-09-30 | money | total_assets | 106,170,500,000 United States dollar | superseded | [clm_6F134AACBD0F](/claim/clm_6F134AACBD0F.md)
- 2010-06-30 to 2010-09-30 | money | total_equity | 55,231,700,000 United States dollar | superseded | [clm_FB8799A4CF05](/claim/clm_FB8799A4CF05.md)
- 2010-07-30 to 2010-10-29 | money | shares_outstanding | 3,073,593,302 shares | superseded | [clm_E46983415AD5](/claim/clm_E46983415AD5.md)
- 2010-09-30 to 2010-12-31 | money | cash_and_equivalents | 9,874,400,000 United States dollar | superseded | [clm_CED915E12E43](/claim/clm_CED915E12E43.md)
- 2010-09-30 to 2011-03-31 | money | quarterly_net_income | 341,600,000 United States dollar | superseded | [clm_12C2D8877AC1](/claim/clm_12C2D8877AC1.md)
- 2010-09-30 to 2011-03-31 | money | quarterly_research_and_development | 2,296,400,000 United States dollar | superseded | [clm_CB134DA21407](/claim/clm_CB134DA21407.md)
- 2010-09-30 to 2011-03-31 | money | quarterly_revenue | 11,124,900,000 United States dollar | superseded | [clm_CAF2B5061F55](/claim/clm_CAF2B5061F55.md)
- 2010-09-30 to 2010-12-31 | money | total_assets | 107,840,100,000 United States dollar | superseded | [clm_8F41253963FE](/claim/clm_8F41253963FE.md)
- 2010-09-30 to 2010-12-31 | money | total_equity | 55,592,800,000 United States dollar | superseded | [clm_A0E18FFDE026](/claim/clm_A0E18FFDE026.md)
- 2010-10-29 to 2011-01-31 | money | shares_outstanding | 3,080,880,847 shares | superseded | [clm_84A1426313AA](/claim/clm_84A1426313AA.md)
- 2010-12-31 to 2011-03-31 | money | cash_and_equivalents | 10,900,000,000 United States dollar | superseded | [clm_2BED9DF30C40](/claim/clm_2BED9DF30C40.md)
- 2010-12-31 to 2011-12-31 | money | net_income | 861,000,000 United States dollar | superseded | [clm_39AC82F2B073](/claim/clm_39AC82F2B073.md)
- 2010-12-31 to 2011-12-31 | money | research_and_development | 10,991,000,000 United States dollar | superseded | [clm_DAC5122F3F04](/claim/clm_DAC5122F3F04.md)
- 2010-12-31 to 2016-12-31 | money | revenue | 45,987,000,000 United States dollar | superseded | [clm_6B2D64844C16](/claim/clm_6B2D64844C16.md)
- 2010-12-31 to 2011-03-31 | money | total_assets | 105,781,000,000 United States dollar | superseded | [clm_6FC7FC088DC8](/claim/clm_6FC7FC088DC8.md)
- 2010-12-31 to 2011-03-31 | money | total_equity | 54,376,000,000 United States dollar | superseded | [clm_254D7953C206](/claim/clm_254D7953C206.md)

## 2011

- 2011-01-31 to 2011-04-29 | money | shares_outstanding | 3,083,080,697 shares | superseded | [clm_9BF1CD5FE3CA](/claim/clm_9BF1CD5FE3CA.md)
- 2011-03-31 to 2011-06-30 | money | cash_and_equivalents | 11,695,000,000 United States dollar | superseded | [clm_138E9F8C2AD6](/claim/clm_138E9F8C2AD6.md)
- 2011-03-31 to 2011-06-30 | money | quarterly_net_income | 1,043,000,000 United States dollar | superseded | [clm_65A1060B45EF](/claim/clm_65A1060B45EF.md)
- 2011-03-31 to 2011-06-30 | money | quarterly_research_and_development | 2,158,000,000 United States dollar | superseded | [clm_3319A0215022](/claim/clm_3319A0215022.md)
- 2011-03-31 to 2017-06-30 | money | quarterly_revenue | 11,580,000,000 United States dollar | superseded | [clm_DD04D89D847D](/claim/clm_DD04D89D847D.md)
- 2011-03-31 to 2011-06-30 | money | total_assets | 105,865,000,000 United States dollar | superseded | [clm_3B74FEDC21AF](/claim/clm_3B74FEDC21AF.md)
- 2011-03-31 to 2011-06-30 | money | total_equity | 54,384,000,000 United States dollar | superseded | [clm_A3FD179A993F](/claim/clm_A3FD179A993F.md)
- 2011-04-29 to 2011-07-29 | money | shares_outstanding | 3,086,584,896 shares | superseded | [clm_6E96761DDE05](/claim/clm_6E96761DDE05.md)
- 2011-06-30 to 2011-09-30 | money | cash_and_equivalents | 12,342,000,000 United States dollar | superseded | [clm_7C24258D5116](/claim/clm_7C24258D5116.md)
- 2011-06-30 to 2011-09-30 | money | quarterly_net_income | 2,024,000,000 United States dollar | superseded | [clm_4193E1EB977C](/claim/clm_4193E1EB977C.md)
- 2011-06-30 to 2011-09-30 | money | quarterly_research_and_development | 1,936,000,000 United States dollar | superseded | [clm_1C2CAA0EE3AB](/claim/clm_1C2CAA0EE3AB.md)
- 2011-06-30 to 2011-09-30 | money | total_assets | 106,195,000,000 United States dollar | superseded | [clm_FA9DB79A8B0C](/claim/clm_FA9DB79A8B0C.md)
- 2011-06-30 to 2011-09-30 | money | total_equity | 55,496,000,000 United States dollar | superseded | [clm_33FE8193CAC6](/claim/clm_33FE8193CAC6.md)
- 2011-07-29 to 2011-10-31 | money | shares_outstanding | 3,080,796,992 shares | superseded | [clm_BA6238CBFDB6](/claim/clm_BA6238CBFDB6.md)
- 2011-09-30 to 2011-12-31 | money | cash_and_equivalents | 14,253,000,000 United States dollar | superseded | [clm_F02B729073B0](/claim/clm_F02B729073B0.md)
- 2011-09-30 to 2012-03-31 | money | quarterly_net_income | 1,692,000,000 United States dollar | superseded | [clm_963AB2E89F87](/claim/clm_963AB2E89F87.md)
- 2011-09-30 to 2012-03-31 | money | quarterly_research_and_development | 1,954,000,000 United States dollar | superseded | [clm_1F7AAAEEBAA8](/claim/clm_1F7AAAEEBAA8.md)
- 2011-09-30 to 2011-12-31 | money | total_assets | 106,534,000,000 United States dollar | superseded | [clm_D995E1344989](/claim/clm_D995E1344989.md)
- 2011-09-30 to 2011-12-31 | money | total_equity | 55,140,000,000 United States dollar | superseded | [clm_E7890C41F190](/claim/clm_E7890C41F190.md)
- 2011-10-31 to 2012-01-31 | money | shares_outstanding | 3,047,921,407 shares | superseded | [clm_C5688CBF2599](/claim/clm_C5688CBF2599.md)
- 2011-12-31 to 2012-03-31 | money | cash_and_equivalents | 13,531,000,000 United States dollar | superseded | [clm_253292471BFE](/claim/clm_253292471BFE.md)
- 2011-12-31 to 2012-12-31 | money | net_income | 6,272,000,000 United States dollar | superseded | [clm_7A9570A80387](/claim/clm_7A9570A80387.md)
- 2011-12-31 to 2012-12-31 | money | research_and_development | 8,467,000,000 United States dollar | superseded | [clm_6551D4B7258D](/claim/clm_6551D4B7258D.md)
- 2011-12-31 to 2012-03-31 | money | total_assets | 105,128,000,000 United States dollar | superseded | [clm_42F08F87AE73](/claim/clm_42F08F87AE73.md)
- 2011-12-31 to 2012-03-31 | money | total_equity | 54,517,000,000 United States dollar | superseded | [clm_1A15195A46D3](/claim/clm_1A15195A46D3.md)

## 2012

- 2012-01-31 to 2012-04-30 | money | shares_outstanding | 3,044,008,396 shares | superseded | [clm_FC3671A94172](/claim/clm_FC3671A94172.md)
- 2012-03-31 to 2012-06-30 | money | cash_and_equivalents | 14,656,000,000 United States dollar | superseded | [clm_5152EB930B57](/claim/clm_5152EB930B57.md)
- 2012-03-31 to 2012-06-30 | money | quarterly_net_income | 1,738,000,000 United States dollar | superseded | [clm_AD058299EEE7](/claim/clm_AD058299EEE7.md)
- 2012-03-31 to 2012-06-30 | money | quarterly_research_and_development | 1,862,000,000 United States dollar | superseded | [clm_95A2A8BB89F6](/claim/clm_95A2A8BB89F6.md)
- 2012-03-31 to 2012-06-30 | money | total_assets | 105,509,000,000 United States dollar | superseded | [clm_F0A7F5A9AE14](/claim/clm_F0A7F5A9AE14.md)
- 2012-03-31 to 2012-06-30 | money | total_equity | 54,860,000,000 United States dollar | superseded | [clm_1BEC26313598](/claim/clm_1BEC26313598.md)
- 2012-04-30 to 2012-07-31 | money | shares_outstanding | 3,041,564,692 shares | superseded | [clm_5053AEF3E520](/claim/clm_5053AEF3E520.md)
- 2012-06-30 to 2012-09-30 | money | cash_and_equivalents | 16,752,000,000 United States dollar | superseded | [clm_7FF9FF3EAA65](/claim/clm_7FF9FF3EAA65.md)
- 2012-06-30 to 2012-09-30 | money | quarterly_net_income | 1,793,000,000 United States dollar | superseded | [clm_13272BAF15D6](/claim/clm_13272BAF15D6.md)
- 2012-06-30 to 2012-09-30 | money | quarterly_research_and_development | 2,165,000,000 United States dollar | superseded | [clm_5897CB0342BB](/claim/clm_5897CB0342BB.md)
- 2012-06-30 to 2012-09-30 | money | total_assets | 105,525,000,000 United States dollar | superseded | [clm_7AC0686FEEC4](/claim/clm_7AC0686FEEC4.md)
- 2012-06-30 to 2012-09-30 | money | total_equity | 55,194,000,000 United States dollar | superseded | [clm_6D6AE389AC7E](/claim/clm_6D6AE389AC7E.md)
- 2012-07-31 to 2012-10-31 | money | shares_outstanding | 3,045,632,274 shares | superseded | [clm_79BF421588A8](/claim/clm_79BF421588A8.md)
- 2012-09-30 to 2012-12-31 | money | cash_and_equivalents | 17,360,000,000 United States dollar | superseded | [clm_395E0D5CE587](/claim/clm_395E0D5CE587.md)
- 2012-09-30 to 2013-03-31 | money | quarterly_net_income | 1,729,000,000 United States dollar | superseded | [clm_286B9F63C75F](/claim/clm_286B9F63C75F.md)
- 2012-09-30 to 2013-03-31 | money | quarterly_research_and_development | 1,918,000,000 United States dollar | superseded | [clm_C41FF0FA4FEA](/claim/clm_C41FF0FA4FEA.md)
- 2012-09-30 to 2012-12-31 | money | total_assets | 106,301,000,000 United States dollar | superseded | [clm_CA202DF46EB3](/claim/clm_CA202DF46EB3.md)
- 2012-09-30 to 2012-12-31 | money | total_equity | 55,747,000,000 United States dollar | superseded | [clm_70F74D2F16D3](/claim/clm_70F74D2F16D3.md)
- 2012-10-31 to 2013-01-31 | money | shares_outstanding | 3,040,071,937 shares | superseded | [clm_850BEDD17E38](/claim/clm_850BEDD17E38.md)
- 2012-12-31 to 2013-03-31 | money | cash_and_equivalents | 13,451,000,000 United States dollar | superseded | [clm_61010F0E4CF3](/claim/clm_61010F0E4CF3.md)
- 2012-12-31 to 2013-12-31 | money | net_income | 6,168,000,000 United States dollar | superseded | [clm_6A173E23DD15](/claim/clm_6A173E23DD15.md)
- 2012-12-31 to 2013-12-31 | money | research_and_development | 8,168,000,000 United States dollar | superseded | [clm_54A1A6CA4C2B](/claim/clm_54A1A6CA4C2B.md)
- 2012-12-31 to 2013-03-31 | money | total_assets | 106,132,000,000 United States dollar | superseded | [clm_74DBDC2276F6](/claim/clm_74DBDC2276F6.md)
- 2012-12-31 to 2013-03-31 | money | total_equity | 53,020,000,000 United States dollar | superseded | [clm_974390ADF164](/claim/clm_974390ADF164.md)

## 2013

- 2013-01-31 to 2013-04-30 | money | shares_outstanding | 3,022,367,538 shares | superseded | [clm_8D39CFAFEB7C](/claim/clm_8D39CFAFEB7C.md)
- 2013-03-31 to 2013-06-30 | money | cash_and_equivalents | 13,024,000,000 United States dollar | superseded | [clm_90FA1C2EE047](/claim/clm_90FA1C2EE047.md)
- 2013-03-31 to 2013-06-30 | money | quarterly_net_income | 1,593,000,000 United States dollar | superseded | [clm_283B3063FEFA](/claim/clm_283B3063FEFA.md)
- 2013-03-31 to 2013-06-30 | money | quarterly_research_and_development | 1,907,000,000 United States dollar | superseded | [clm_911FFD783AD9](/claim/clm_911FFD783AD9.md)
- 2013-03-31 to 2013-06-30 | money | total_assets | 106,200,000,000 United States dollar | superseded | [clm_AB6793F263FE](/claim/clm_AB6793F263FE.md)
- 2013-03-31 to 2013-06-30 | money | total_equity | 53,029,000,000 United States dollar | superseded | [clm_9DD1E2DA6948](/claim/clm_9DD1E2DA6948.md)
- 2013-04-30 to 2013-07-31 | money | shares_outstanding | 3,019,611,844 shares | superseded | [clm_11D540F5CFF2](/claim/clm_11D540F5CFF2.md)
- 2013-06-30 to 2013-09-30 | money | cash_and_equivalents | 15,090,000,000 United States dollar | superseded | [clm_494220063F74](/claim/clm_494220063F74.md)
- 2013-06-30 to 2013-09-30 | money | quarterly_net_income | 906,000,000 United States dollar | superseded | [clm_9DA08D3D51BF](/claim/clm_9DA08D3D51BF.md)
- 2013-06-30 to 2013-09-30 | money | quarterly_research_and_development | 2,101,000,000 United States dollar | superseded | [clm_866963D28A7C](/claim/clm_866963D28A7C.md)
- 2013-06-30 to 2013-09-30 | money | total_assets | 106,876,000,000 United States dollar | superseded | [clm_DCC0FF436A6C](/claim/clm_DCC0FF436A6C.md)
- 2013-06-30 to 2013-09-30 | money | total_equity | 47,500,000,000 United States dollar | superseded | [clm_8979652BD6C4](/claim/clm_8979652BD6C4.md)
- 2013-07-31 to 2013-10-31 | money | shares_outstanding | 2,926,375,532 shares | superseded | [clm_A36CCC65D836](/claim/clm_A36CCC65D836.md)
- 2013-09-30 to 2013-12-31 | money | cash_and_equivalents | 14,090,000,000 United States dollar | superseded | [clm_A29E493EA927](/claim/clm_A29E493EA927.md)
- 2013-09-30 to 2014-03-31 | money | quarterly_net_income | 1,124,000,000 United States dollar | superseded | [clm_E3E08B5ED822](/claim/clm_E3E08B5ED822.md)
- 2013-09-30 to 2014-03-31 | money | quarterly_research_and_development | 1,660,000,000 United States dollar | superseded | [clm_E70B4951C373](/claim/clm_E70B4951C373.md)
- 2013-09-30 to 2013-12-31 | money | total_assets | 106,419,000,000 United States dollar | superseded | [clm_9EF1364229B5](/claim/clm_9EF1364229B5.md)
- 2013-09-30 to 2013-12-31 | money | total_equity | 47,419,000,000 United States dollar | superseded | [clm_1EC02EAE4AB2](/claim/clm_1EC02EAE4AB2.md)
- 2013-10-31 to 2014-01-31 | money | shares_outstanding | 2,921,928,875 shares | superseded | [clm_5DBCAF2D77B1](/claim/clm_5DBCAF2D77B1.md)
- 2013-12-31 to 2014-03-31 | money | cash_and_equivalents | 15,621,000,000 United States dollar | superseded | [clm_A5D39D3E54E7](/claim/clm_A5D39D3E54E7.md)
- 2013-12-31 to 2014-12-31 | money | net_income | 4,404,000,000 United States dollar | superseded | [clm_E27BC8C8DD77](/claim/clm_E27BC8C8DD77.md)
- 2013-12-31 to 2014-12-31 | money | research_and_development | 7,503,000,000 United States dollar | superseded | [clm_229317196120](/claim/clm_229317196120.md)
- 2013-12-31 to 2014-03-31 | money | total_assets | 105,645,000,000 United States dollar | superseded | [clm_18DE3EDE6596](/claim/clm_18DE3EDE6596.md)
- 2013-12-31 to 2014-03-31 | money | total_equity | 49,765,000,000 United States dollar | superseded | [clm_A0F5C187BF3E](/claim/clm_A0F5C187BF3E.md)

## 2014

- 2014-01-31 to 2014-04-30 | money | shares_outstanding | 2,940,622,461 shares | superseded | [clm_2416DCFDB05C](/claim/clm_2416DCFDB05C.md)
- 2014-03-31 to 2014-06-30 | money | cash_and_equivalents | 15,828,000,000 United States dollar | superseded | [clm_210F97389E0B](/claim/clm_210F97389E0B.md)
- 2014-03-31 to 2014-06-30 | money | quarterly_net_income | 1,705,000,000 United States dollar | superseded | [clm_E212531659DD](/claim/clm_E212531659DD.md)
- 2014-03-31 to 2014-06-30 | money | quarterly_research_and_development | 1,574,000,000 United States dollar | superseded | [clm_05F2BFB4125E](/claim/clm_05F2BFB4125E.md)
- 2014-03-31 to 2014-06-30 | money | total_assets | 108,460,000,000 United States dollar | superseded | [clm_A09FA8993177](/claim/clm_A09FA8993177.md)
- 2014-03-31 to 2014-06-30 | money | total_equity | 49,975,000,000 United States dollar | superseded | [clm_8BA31BB74F0A](/claim/clm_8BA31BB74F0A.md)
- 2014-04-30 to 2014-07-31 | money | shares_outstanding | 2,922,376,244 shares | superseded | [clm_E265F2EB9492](/claim/clm_E265F2EB9492.md)
- 2014-06-30 to 2014-09-30 | money | cash_and_equivalents | 9,743,000,000 United States dollar | superseded | [clm_C51678D27969](/claim/clm_C51678D27969.md)
- 2014-06-30 to 2014-09-30 | money | quarterly_net_income | 2,004,000,000 United States dollar | superseded | [clm_F00D1BA511E6](/claim/clm_F00D1BA511E6.md)
- 2014-06-30 to 2014-09-30 | money | quarterly_research_and_development | 1,664,000,000 United States dollar | superseded | [clm_911F877CC3E3](/claim/clm_911F877CC3E3.md)
- 2014-06-30 to 2014-09-30 | money | total_assets | 97,860,000,000 United States dollar | superseded | [clm_C6D2D1307E74](/claim/clm_C6D2D1307E74.md)
- 2014-06-30 to 2014-09-30 | money | total_equity | 48,358,000,000 United States dollar | superseded | [clm_94E54F01B864](/claim/clm_94E54F01B864.md)
- 2014-07-31 to 2014-10-31 | money | shares_outstanding | 2,884,632,033 shares | superseded | [clm_5853AEBD7F61](/claim/clm_5853AEBD7F61.md)
- 2014-09-30 to 2014-12-31 | money | cash_and_equivalents | 11,370,000,000 United States dollar | superseded | [clm_62E7AB824032](/claim/clm_62E7AB824032.md)
- 2014-09-30 to 2015-03-31 | money | quarterly_net_income | 895,000,000 United States dollar | superseded | [clm_693AD5707AD7](/claim/clm_693AD5707AD7.md)
- 2014-09-30 to 2015-03-31 | money | quarterly_research_and_development | 1,659,000,000 United States dollar | superseded | [clm_49837366C97C](/claim/clm_49837366C97C.md)
- 2014-09-30 to 2014-12-31 | money | total_assets | 101,808,000,000 United States dollar | superseded | [clm_3A6CAF21DAAA](/claim/clm_3A6CAF21DAAA.md)
- 2014-09-30 to 2014-12-31 | money | total_equity | 45,224,000,000 United States dollar | superseded | [clm_89371CE7088F](/claim/clm_89371CE7088F.md)
- 2014-10-31 to 2015-01-31 | money | shares_outstanding | 2,850,873,371 shares | superseded | [clm_F28C55B6A7FE](/claim/clm_F28C55B6A7FE.md)
- 2014-12-31 to 2015-03-31 | money | cash_and_equivalents | 7,441,000,000 United States dollar | superseded | [clm_89F2FC090FA9](/claim/clm_89F2FC090FA9.md)
- 2014-12-31 to 2015-12-31 | money | net_income | 11,920,000,000 United States dollar | superseded | [clm_480EA42C5F46](/claim/clm_480EA42C5F46.md)
- 2014-12-31 to 2015-12-31 | money | research_and_development | 7,180,000,000 United States dollar | superseded | [clm_7B46759F0E5E](/claim/clm_7B46759F0E5E.md)
- 2014-12-31 to 2015-03-31 | money | total_assets | 98,335,000,000 United States dollar | superseded | [clm_18E23DA639C2](/claim/clm_18E23DA639C2.md)
- 2014-12-31 to 2015-03-31 | money | total_equity | 48,647,000,000 United States dollar | superseded | [clm_0E5197A56A4E](/claim/clm_0E5197A56A4E.md)

## 2015

- 2015-01-31 to 2015-04-30 | money | shares_outstanding | 2,838,192,933 shares | superseded | [clm_3B9D279D2011](/claim/clm_3B9D279D2011.md)
- 2015-03-31 to 2015-06-30 | money | cash_and_equivalents | 7,980,000,000 United States dollar | superseded | [clm_49402CF1E6AD](/claim/clm_49402CF1E6AD.md)
- 2015-03-31 to 2015-06-30 | money | quarterly_net_income | 953,000,000 United States dollar | superseded | [clm_EA4D3DE6DF4C](/claim/clm_EA4D3DE6DF4C.md)
- 2015-03-31 to 2015-06-30 | money | quarterly_research_and_development | 1,737,000,000 United States dollar | superseded | [clm_B147AAA7DA5F](/claim/clm_B147AAA7DA5F.md)
- 2015-03-31 to 2015-06-30 | money | total_assets | 108,345,000,000 United States dollar | superseded | [clm_3053C11D0C03](/claim/clm_3053C11D0C03.md)
- 2015-03-31 to 2015-06-30 | money | total_equity | 47,765,000,000 United States dollar | superseded | [clm_22FB10ADCE7F](/claim/clm_22FB10ADCE7F.md)
- 2015-04-30 to 2015-07-31 | money | shares_outstanding | 2,825,221,749 shares | superseded | [clm_14F0931A2C29](/claim/clm_14F0931A2C29.md)
- 2015-06-30 to 2015-09-30 | money | cash_and_equivalents | 6,922,000,000 United States dollar | superseded | [clm_6919D2A6E878](/claim/clm_6919D2A6E878.md)
- 2015-06-30 to 2015-09-30 | money | quarterly_net_income | 687,000,000 United States dollar | superseded | [clm_580CDBD2CB5C](/claim/clm_580CDBD2CB5C.md)
- 2015-06-30 to 2015-09-30 | money | quarterly_research_and_development | 1,670,000,000 United States dollar | superseded | [clm_19CFD7F8FB0B](/claim/clm_19CFD7F8FB0B.md)
- 2015-06-30 to 2015-09-30 | money | total_assets | 102,582,000,000 United States dollar | superseded | [clm_1A67A4E05244](/claim/clm_1A67A4E05244.md)
- 2015-06-30 to 2015-09-30 | money | total_equity | 46,448,000,000 United States dollar | superseded | [clm_39A0C18651A0](/claim/clm_39A0C18651A0.md)
- 2015-07-31 to 2015-10-31 | money | shares_outstanding | 2,816,635,020 shares | superseded | [clm_53616B87641B](/claim/clm_53616B87641B.md)
- 2015-09-30 to 2015-12-31 | money | cash_and_equivalents | 7,548,000,000 United States dollar | superseded | [clm_59257E5213FA](/claim/clm_59257E5213FA.md)
- 2015-09-30 to 2016-03-31 | money | quarterly_net_income | 1,826,000,000 United States dollar | superseded | [clm_CDDC90397241](/claim/clm_CDDC90397241.md)
- 2015-09-30 to 2016-03-31 | money | quarterly_research_and_development | 1,500,000,000 United States dollar | superseded | [clm_AC2912FEAAED](/claim/clm_AC2912FEAAED.md)
- 2015-09-30 to 2015-12-31 | money | total_assets | 101,232,000,000 United States dollar | superseded | [clm_A47DE2B24AF2](/claim/clm_A47DE2B24AF2.md)
- 2015-09-30 to 2015-12-31 | money | total_equity | 45,587,000,000 United States dollar | superseded | [clm_15359FB5299B](/claim/clm_15359FB5299B.md)
- 2015-10-31 to 2016-01-31 | money | shares_outstanding | 2,793,543,137 shares | superseded | [clm_1C1225C23E40](/claim/clm_1C1225C23E40.md)
- 2015-12-31 to 2016-03-31 | money | cash_and_equivalents | 8,524,000,000 United States dollar | superseded | [clm_7BDCD397A17D](/claim/clm_7BDCD397A17D.md)
- 2015-12-31 to 2016-12-31 | money | net_income | 4,442,000,000 United States dollar | superseded | [clm_5192469BE119](/claim/clm_5192469BE119.md)
- 2015-12-31 to 2016-12-31 | money | research_and_development | 6,704,000,000 United States dollar | superseded | [clm_D52E6DA72BE9](/claim/clm_D52E6DA72BE9.md)
- 2015-12-31 to 2016-03-31 | money | total_assets | 101,779,000,000 United States dollar | superseded | [clm_FEF2D6BB7989](/claim/clm_FEF2D6BB7989.md)
- 2015-12-31 to 2016-03-31 | money | total_equity | 44,676,000,000 United States dollar | superseded | [clm_F89730A7CEBD](/claim/clm_F89730A7CEBD.md)

## 2016

- 2016-01-31 to 2016-04-30 | money | shares_outstanding | 2,775,258,591 shares | superseded | [clm_3AABB9FFA15E](/claim/clm_3AABB9FFA15E.md)
- 2016-03-31 to 2016-06-30 | money | cash_and_equivalents | 9,716,000,000 United States dollar | superseded | [clm_825172ED4990](/claim/clm_825172ED4990.md)
- 2016-03-31 to 2016-06-30 | money | quarterly_net_income | 1,125,000,000 United States dollar | superseded | [clm_85649A72C697](/claim/clm_85649A72C697.md)
- 2016-03-31 to 2016-06-30 | money | quarterly_research_and_development | 1,659,000,000 United States dollar | superseded | [clm_D488C57B0FAA](/claim/clm_D488C57B0FAA.md)
- 2016-03-31 to 2016-06-30 | money | total_assets | 98,755,000,000 United States dollar | superseded | [clm_288991751ADB](/claim/clm_288991751ADB.md)
- 2016-03-31 to 2016-06-30 | money | total_equity | 43,806,000,000 United States dollar | superseded | [clm_D96A931644FC](/claim/clm_D96A931644FC.md)
- 2016-04-30 to 2016-07-31 | money | shares_outstanding | 2,768,025,348 shares | superseded | [clm_76492752CBD6](/claim/clm_76492752CBD6.md)
- 2016-06-30 to 2016-09-30 | money | cash_and_equivalents | 6,608,000,000 United States dollar | superseded | [clm_A89A271BF7E1](/claim/clm_A89A271BF7E1.md)
- 2016-06-30 to 2016-09-30 | money | quarterly_net_income | 1,205,000,000 United States dollar | superseded | [clm_C2D709880E62](/claim/clm_C2D709880E62.md)
- 2016-06-30 to 2016-09-30 | money | quarterly_research_and_development | 2,151,000,000 United States dollar | superseded | [clm_4FDF2F5B4857](/claim/clm_4FDF2F5B4857.md)
- 2016-06-30 to 2016-09-30 | money | total_assets | 96,475,000,000 United States dollar | superseded | [clm_CFF0D674C75A](/claim/clm_CFF0D674C75A.md)
- 2016-06-30 to 2016-09-30 | money | total_equity | 43,357,000,000 United States dollar | superseded | [clm_86A8CB1D7187](/claim/clm_86A8CB1D7187.md)
- 2016-07-31 to 2016-10-31 | money | shares_outstanding | 2,765,208,203 shares | superseded | [clm_42D5BA4A587B](/claim/clm_42D5BA4A587B.md)
- 2016-09-30 to 2016-12-31 | money | cash_and_equivalents | 7,907,000,000 United States dollar | superseded | [clm_437CAECBFA51](/claim/clm_437CAECBFA51.md)
- 2016-09-30 to 2017-03-31 | money | quarterly_net_income | 2,184,000,000 United States dollar | superseded | [clm_8C42F3B5F24C](/claim/clm_8C42F3B5F24C.md)
- 2016-09-30 to 2017-03-31 | money | quarterly_research_and_development | 1,664,000,000 United States dollar | superseded | [clm_E2DBCCAAB311](/claim/clm_E2DBCCAAB311.md)
- 2016-09-30 to 2016-12-31 | money | total_assets | 98,335,000,000 United States dollar | superseded | [clm_CEE60B020EE0](/claim/clm_CEE60B020EE0.md)
- 2016-09-30 to 2016-12-31 | money | total_equity | 43,744,000,000 United States dollar | superseded | [clm_96D16DB08BF3](/claim/clm_96D16DB08BF3.md)
- 2016-10-31 to 2017-01-31 | money | shares_outstanding | 2,757,137,517 shares | superseded | [clm_9225D2BB085B](/claim/clm_9225D2BB085B.md)
- 2016-12-31 to 2017-03-31 | money | cash_and_equivalents | 6,515,000,000 United States dollar | superseded | [clm_296D7E29A85C](/claim/clm_296D7E29A85C.md)
- 2016-12-31 to 2017-12-31 | money | net_income | 3,920,000,000 United States dollar | superseded | [clm_2F97411688D4](/claim/clm_2F97411688D4.md)
- 2016-12-31 to 2017-12-31 | money | research_and_development | 10,124,000,000 United States dollar | superseded | [clm_8B7063543990](/claim/clm_8B7063543990.md)
- 2016-12-31 to 2017-12-31 | money | revenue | 39,807,000,000 United States dollar | superseded | [clm_B3973E2ADB22](/claim/clm_B3973E2ADB22.md)
- 2016-12-31 to 2017-03-31 | money | total_assets | 95,377,000,000 United States dollar | superseded | [clm_9C0CF77D801C](/claim/clm_9C0CF77D801C.md)
- 2016-12-31 to 2017-03-31 | money | total_equity | 40,088,000,000 United States dollar | superseded | [clm_F4558D2EB9F0](/claim/clm_F4558D2EB9F0.md)

## 2017

- 2017-01-31 to 2017-04-30 | money | shares_outstanding | 2,745,571,067 shares | superseded | [clm_3E4686F1C38B](/claim/clm_3E4686F1C38B.md)
- 2017-03-31 to 2017-06-30 | money | cash_and_equivalents | 11,708,000,000 United States dollar | superseded | [clm_372309F7322C](/claim/clm_372309F7322C.md)
- 2017-03-31 to 2017-06-30 | money | quarterly_net_income | 1,551,000,000 United States dollar | superseded | [clm_0CA94408597F](/claim/clm_0CA94408597F.md)
- 2017-03-31 to 2017-06-30 | money | quarterly_research_and_development | 1,796,000,000 United States dollar | superseded | [clm_E6943054D4C9](/claim/clm_E6943054D4C9.md)
- 2017-03-31 to 2017-06-30 | money | total_assets | 96,561,000,000 United States dollar | superseded | [clm_92759280B530](/claim/clm_92759280B530.md)
- 2017-03-31 to 2017-06-30 | money | total_equity | 39,837,000,000 United States dollar | superseded | [clm_8BB7754D3964](/claim/clm_8BB7754D3964.md)
- 2017-04-30 to 2017-07-31 | money | shares_outstanding | 2,735,164,510 shares | superseded | [clm_17404A75E250](/claim/clm_17404A75E250.md)
- 2017-06-30 to 2017-09-30 | money | cash_and_equivalents | 7,786,000,000 United States dollar | superseded | [clm_069AC1ED0F10](/claim/clm_069AC1ED0F10.md)
- 2017-06-30 to 2017-09-30 | money | quarterly_net_income | 1,946,000,000 United States dollar | superseded | [clm_4DB34C3A4F05](/claim/clm_4DB34C3A4F05.md)
- 2017-06-30 to 2017-09-30 | money | quarterly_research_and_development | 1,749,000,000 United States dollar | superseded | [clm_3B507E46CC5D](/claim/clm_3B507E46CC5D.md)
- 2017-06-30 to 2017-09-30 | money | quarterly_revenue | 9,930,000,000 United States dollar | superseded | [clm_02E1EC40EBB1](/claim/clm_02E1EC40EBB1.md)
- 2017-06-30 to 2017-09-30 | money | total_assets | 92,804,000,000 United States dollar | superseded | [clm_8BFD8488B3A5](/claim/clm_8BFD8488B3A5.md)
- 2017-06-30 to 2017-09-30 | money | total_equity | 39,463,000,000 United States dollar | superseded | [clm_868E075D6D61](/claim/clm_868E075D6D61.md)
- 2017-07-31 to 2017-10-31 | money | shares_outstanding | 2,727,354,340 shares | superseded | [clm_EEE6786E9E9E](/claim/clm_EEE6786E9E9E.md)
- 2017-09-30 to 2017-12-31 | money | cash_and_equivalents | 7,901,000,000 United States dollar | superseded | [clm_B47A627983F0](/claim/clm_B47A627983F0.md)
- 2017-09-30 to 2018-03-31 | money | quarterly_net_income | -56,000,000 United States dollar | superseded | [clm_B00F52FDD238](/claim/clm_B00F52FDD238.md)
- 2017-09-30 to 2018-03-31 | money | quarterly_research_and_development | 4,383,000,000 United States dollar | superseded | [clm_393DB4682B31](/claim/clm_393DB4682B31.md)
- 2017-09-30 to 2018-03-31 | money | quarterly_revenue | 10,325,000,000 United States dollar | superseded | [clm_CE4B75CB7BCE](/claim/clm_CE4B75CB7BCE.md)
- 2017-09-30 to 2017-12-31 | money | total_assets | 91,676,000,000 United States dollar | superseded | [clm_C6F722C9950C](/claim/clm_C6F722C9950C.md)
- 2017-09-30 to 2017-12-31 | money | total_equity | 38,248,000,000 United States dollar | superseded | [clm_207F5C0875B9](/claim/clm_207F5C0875B9.md)
- 2017-10-31 to 2018-01-31 | money | shares_outstanding | 2,724,436,835 shares | superseded | [clm_9F2CDB05F1E9](/claim/clm_9F2CDB05F1E9.md)
- 2017-12-31 to 2018-03-31 | money | cash_and_equivalents | 6,092,000,000 United States dollar | superseded | [clm_232F37648DD2](/claim/clm_232F37648DD2.md)
- 2017-12-31 to 2018-12-31 | money | net_income | 2,394,000,000 United States dollar | superseded | [clm_C317F9A41D65](/claim/clm_C317F9A41D65.md)
- 2017-12-31 to 2018-12-31 | money | research_and_development | 10,208,000,000 United States dollar | superseded | [clm_C217AE3D4BB6](/claim/clm_C217AE3D4BB6.md)
- 2017-12-31 to 2018-12-31 | money | revenue | 40,122,000,000 United States dollar | superseded | [clm_1145C38DDEF9](/claim/clm_1145C38DDEF9.md)
- 2017-12-31 to 2018-03-31 | money | total_assets | 87,872,000,000 United States dollar | superseded | [clm_2BFBBD91DD20](/claim/clm_2BFBBD91DD20.md)
- 2017-12-31 to 2018-03-31 | money | total_equity | 34,336,000,000 United States dollar | superseded | [clm_BC24AF78EFCB](/claim/clm_BC24AF78EFCB.md)

## 2018

- 2018-01-31 to 2018-04-30 | money | shares_outstanding | 2,696,190,502 shares | superseded | [clm_EE7BE5F78BEA](/claim/clm_EE7BE5F78BEA.md)
- 2018-03-31 to 2018-06-30 | money | cash_and_equivalents | 4,483,000,000 United States dollar | superseded | [clm_C199DABE1F23](/claim/clm_C199DABE1F23.md)
- 2018-03-31 to 2018-06-30 | money | quarterly_net_income | 736,000,000 United States dollar | superseded | [clm_D25BE24533C1](/claim/clm_D25BE24533C1.md)
- 2018-03-31 to 2018-06-30 | money | quarterly_research_and_development | 3,196,000,000 United States dollar | superseded | [clm_72F018D1F42C](/claim/clm_72F018D1F42C.md)
- 2018-03-31 to 2018-06-30 | money | quarterly_revenue | 10,037,000,000 United States dollar | superseded | [clm_E8AC27AFE10B](/claim/clm_E8AC27AFE10B.md)
- 2018-03-31 to 2018-06-30 | money | total_assets | 86,041,000,000 United States dollar | superseded | [clm_B05C96267A31](/claim/clm_B05C96267A31.md)
- 2018-03-31 to 2018-06-30 | money | total_equity | 33,668,000,000 United States dollar | superseded | [clm_600C98D7D769](/claim/clm_600C98D7D769.md)
- 2018-04-30 to 2018-07-31 | money | shares_outstanding | 2,690,303,898 shares | superseded | [clm_5CB49AA3F905](/claim/clm_5CB49AA3F905.md)
- 2018-06-30 to 2018-09-30 | money | cash_and_equivalents | 5,310,000,000 United States dollar | superseded | [clm_AAA255A07687](/claim/clm_AAA255A07687.md)
- 2018-06-30 to 2018-09-30 | money | quarterly_net_income | 1,707,000,000 United States dollar | superseded | [clm_B18491AB2F19](/claim/clm_B18491AB2F19.md)
- 2018-06-30 to 2018-09-30 | money | quarterly_research_and_development | 2,274,000,000 United States dollar | superseded | [clm_FD39BFA827F7](/claim/clm_FD39BFA827F7.md)
- 2018-06-30 to 2018-09-30 | money | quarterly_revenue | 10,465,000,000 United States dollar | superseded | [clm_EAA01F078C81](/claim/clm_EAA01F078C81.md)
- 2018-06-30 to 2018-09-30 | money | total_assets | 85,040,000,000 United States dollar | superseded | [clm_00D624D3F6C6](/claim/clm_00D624D3F6C6.md)
- 2018-06-30 to 2018-09-30 | money | total_equity | 32,529,000,000 United States dollar | superseded | [clm_BF9BD7C5474F](/claim/clm_BF9BD7C5474F.md)
- 2018-07-31 to 2018-10-31 | money | shares_outstanding | 2,659,525,311 shares | superseded | [clm_0629D11AC216](/claim/clm_0629D11AC216.md)
- 2018-09-30 to 2018-12-31 | money | cash_and_equivalents | 7,826,000,000 United States dollar | superseded | [clm_B3CC449D09A5](/claim/clm_B3CC449D09A5.md)
- 2018-09-30 to 2019-03-31 | money | quarterly_net_income | 1,950,000,000 United States dollar | superseded | [clm_FC96B547649A](/claim/clm_FC96B547649A.md)
- 2018-09-30 to 2019-03-31 | money | quarterly_research_and_development | 2,068,000,000 United States dollar | superseded | [clm_2724E09F4094](/claim/clm_2724E09F4094.md)
- 2018-09-30 to 2019-03-31 | money | quarterly_revenue | 10,794,000,000 United States dollar | superseded | [clm_E5380D65707D](/claim/clm_E5380D65707D.md)
- 2018-09-30 to 2018-12-31 | money | total_assets | 85,130,000,000 United States dollar | superseded | [clm_F3A459B65CBF](/claim/clm_F3A459B65CBF.md)
- 2018-09-30 to 2018-12-31 | money | total_equity | 32,422,000,000 United States dollar | superseded | [clm_59E105928DAD](/claim/clm_59E105928DAD.md)
- 2018-10-31 to 2019-01-31 | money | shares_outstanding | 2,600,376,500 shares | superseded | [clm_F1CB002B7759](/claim/clm_F1CB002B7759.md)
- 2018-12-31 to 2019-03-31 | money | cash_and_equivalents | 7,965,000,000 United States dollar | superseded | [clm_C4B47494D086](/claim/clm_C4B47494D086.md)
- 2018-12-31 to 2019-12-31 | money | net_income | 6,220,000,000 United States dollar | superseded | [clm_D1FFB154F0E4](/claim/clm_D1FFB154F0E4.md)
- 2018-12-31 to 2019-12-31 | money | research_and_development | 9,752,000,000 United States dollar | superseded | [clm_781231FF91DC](/claim/clm_781231FF91DC.md)
- 2018-12-31 to 2019-12-31 | money | revenue | 42,294,000,000 United States dollar | superseded | [clm_829CCD9C74BC](/claim/clm_829CCD9C74BC.md)
- 2018-12-31 to 2019-03-31 | money | total_assets | 82,637,000,000 United States dollar | superseded | [clm_6CE3449E9C0D](/claim/clm_6CE3449E9C0D.md)
- 2018-12-31 to 2019-03-31 | money | total_equity | 26,701,000,000 United States dollar | superseded | [clm_E57111F73208](/claim/clm_E57111F73208.md)

## 2019

- 2019-01-31 to 2019-04-30 | money | shares_outstanding | 2,581,220,308 shares | superseded | [clm_9AEDFCF6FFF1](/claim/clm_9AEDFCF6FFF1.md)
- 2019-03-31 to 2019-06-30 | money | cash_and_equivalents | 8,076,000,000 United States dollar | superseded | [clm_BA62E6A9ABE6](/claim/clm_BA62E6A9ABE6.md)
- 2019-03-31 to 2019-06-30 | money | quarterly_net_income | 2,915,000,000 United States dollar | superseded | [clm_F508DB33EABE](/claim/clm_F508DB33EABE.md)
- 2019-03-31 to 2019-06-30 | money | quarterly_research_and_development | 1,931,000,000 United States dollar | superseded | [clm_3122AF3523E0](/claim/clm_3122AF3523E0.md)
- 2019-03-31 to 2019-06-30 | money | quarterly_revenue | 10,816,000,000 United States dollar | superseded | [clm_800327091376](/claim/clm_800327091376.md)
- 2019-03-31 to 2019-06-30 | money | total_assets | 82,354,000,000 United States dollar | superseded | [clm_296C5FD003C5](/claim/clm_296C5FD003C5.md)
- 2019-03-31 to 2019-06-30 | money | total_equity | 27,539,000,000 United States dollar | superseded | [clm_7CB401BF90C0](/claim/clm_7CB401BF90C0.md)
- 2019-04-30 to 2019-07-31 | money | shares_outstanding | 2,574,644,410 shares | superseded | [clm_45D07EF51ABE](/claim/clm_45D07EF51ABE.md)
- 2019-06-30 to 2019-09-30 | money | cash_and_equivalents | 6,659,000,000 United States dollar | superseded | [clm_EB2F3D5D01EC](/claim/clm_EB2F3D5D01EC.md)
- 2019-06-30 to 2019-09-30 | money | quarterly_net_income | 2,670,000,000 United States dollar | superseded | [clm_104F474E5C73](/claim/clm_104F474E5C73.md)
- 2019-06-30 to 2019-09-30 | money | quarterly_research_and_development | 2,189,000,000 United States dollar | superseded | [clm_FE9AB4A6BF09](/claim/clm_FE9AB4A6BF09.md)
- 2019-06-30 to 2019-09-30 | money | quarterly_revenue | 11,760,000,000 United States dollar | superseded | [clm_25A17B48A15F](/claim/clm_25A17B48A15F.md)
- 2019-06-30 to 2019-09-30 | money | total_assets | 83,965,000,000 United States dollar | superseded | [clm_07EDDEDB6853](/claim/clm_07EDDEDB6853.md)
- 2019-06-30 to 2019-09-30 | money | total_equity | 27,635,000,000 United States dollar | superseded | [clm_3F564403AA3B](/claim/clm_3F564403AA3B.md)
- 2019-07-31 to 2019-10-31 | money | shares_outstanding | 2,560,374,643 shares | superseded | [clm_24A63371969B](/claim/clm_24A63371969B.md)
- 2019-09-30 to 2019-12-31 | money | cash_and_equivalents | 7,869,000,000 United States dollar | superseded | [clm_13B057D601E9](/claim/clm_13B057D601E9.md)
- 2019-09-30 to 2020-03-31 | money | quarterly_net_income | 1,901,000,000 United States dollar | superseded | [clm_C49B13FDDF3A](/claim/clm_C49B13FDDF3A.md)
- 2019-09-30 to 2020-03-31 | money | quarterly_research_and_development | 3,204,000,000 United States dollar | superseded | [clm_B868BDC6CD31](/claim/clm_B868BDC6CD31.md)
- 2019-09-30 to 2020-03-31 | money | quarterly_revenue | 12,397,000,000 United States dollar | superseded | [clm_3AE77590962D](/claim/clm_3AE77590962D.md)
- 2019-09-30 to 2019-12-31 | money | total_assets | 83,331,000,000 United States dollar | superseded | [clm_DF0DF5E31A2D](/claim/clm_DF0DF5E31A2D.md)
- 2019-09-30 to 2019-12-31 | money | total_equity | 26,838,000,000 United States dollar | superseded | [clm_7CE9BE85C914](/claim/clm_7CE9BE85C914.md)
- 2019-10-31 to 2020-01-31 | money | shares_outstanding | 2,545,984,142 shares | superseded | [clm_EC29FB8F343C](/claim/clm_EC29FB8F343C.md)
- 2019-12-31 to 2020-03-31 | money | cash_and_equivalents | 9,676,000,000 United States dollar | superseded | [clm_F75263B1D61F](/claim/clm_F75263B1D61F.md)
- 2019-12-31 to 2020-12-31 | money | net_income | 9,843,000,000 United States dollar | superseded | [clm_97E52B2371D0](/claim/clm_97E52B2371D0.md)
- 2019-12-31 to 2020-12-31 | money | research_and_development | 9,872,000,000 United States dollar | superseded | [clm_D5BC12D2484C](/claim/clm_D5BC12D2484C.md)
- 2019-12-31 to 2020-12-31 | money | revenue | 46,840,000,000 United States dollar | superseded | [clm_72B03D5517FF](/claim/clm_72B03D5517FF.md)
- 2019-12-31 to 2020-03-31 | money | total_assets | 84,397,000,000 United States dollar | superseded | [clm_029900C42A81](/claim/clm_029900C42A81.md)
- 2019-12-31 to 2020-03-31 | money | total_equity | 25,907,000,000 United States dollar | superseded | [clm_51169445BDC3](/claim/clm_51169445BDC3.md)

## 2020

- 2020-01-31 to 2020-04-30 | money | shares_outstanding | 2,536,268,760 shares | superseded | [clm_B554111539E4](/claim/clm_B554111539E4.md)
- 2020-03-31 to 2020-06-30 | money | cash_and_equivalents | 7,425,000,000 United States dollar | superseded | [clm_2F02734188EA](/claim/clm_2F02734188EA.md)
- 2020-03-31 to 2020-06-30 | money | quarterly_net_income | 3,219,000,000 United States dollar | superseded | [clm_1A9DF101A4EB](/claim/clm_1A9DF101A4EB.md)
- 2020-03-31 to 2020-06-30 | money | quarterly_research_and_development | 2,209,000,000 United States dollar | superseded | [clm_5596F1B23FD3](/claim/clm_5596F1B23FD3.md)
- 2020-03-31 to 2020-06-30 | money | quarterly_revenue | 12,057,000,000 United States dollar | superseded | [clm_E554AD8078D3](/claim/clm_E554AD8078D3.md)
- 2020-03-31 to 2020-06-30 | money | total_assets | 84,913,000,000 United States dollar | superseded | [clm_2A9BC3DD361F](/claim/clm_2A9BC3DD361F.md)
- 2020-03-31 to 2020-06-30 | money | total_equity | 26,205,000,000 United States dollar | superseded | [clm_8230E6A696F5](/claim/clm_8230E6A696F5.md)
- 2020-04-30 to 2020-07-31 | money | shares_outstanding | 2,524,101,191 shares | superseded | [clm_A5759D744830](/claim/clm_A5759D744830.md)
- 2020-06-30 to 2020-09-30 | money | cash_and_equivalents | 11,103,000,000 United States dollar | superseded | [clm_F0C3055A26FF](/claim/clm_F0C3055A26FF.md)
- 2020-06-30 to 2020-09-30 | money | quarterly_net_income | 3,002,000,000 United States dollar | superseded | [clm_F7B34F85A744](/claim/clm_F7B34F85A744.md)
- 2020-06-30 to 2020-09-30 | money | quarterly_research_and_development | 2,123,000,000 United States dollar | superseded | [clm_F21AC6FA6FAB](/claim/clm_F21AC6FA6FAB.md)
- 2020-06-30 to 2020-09-30 | money | quarterly_revenue | 10,872,000,000 United States dollar | superseded | [clm_AFC6EDCC90D8](/claim/clm_AFC6EDCC90D8.md)
- 2020-06-30 to 2020-09-30 | money | total_assets | 90,615,000,000 United States dollar | superseded | [clm_84481BCEF2DA](/claim/clm_84481BCEF2DA.md)
- 2020-06-30 to 2020-09-30 | money | total_equity | 27,642,000,000 United States dollar | superseded | [clm_418AA1D3C2FF](/claim/clm_418AA1D3C2FF.md)
- 2020-07-31 to 2020-10-31 | money | shares_outstanding | 2,529,241,070 shares | superseded | [clm_26BCDBE0EE1C](/claim/clm_26BCDBE0EE1C.md)
- 2020-09-30 to 2020-12-31 | money | cash_and_equivalents | 7,356,000,000 United States dollar | superseded | [clm_3D89E44DB40E](/claim/clm_3D89E44DB40E.md)
- 2020-09-30 to 2021-03-31 | money | quarterly_net_income | 2,941,000,000 United States dollar | superseded | [clm_F4D24DFDC05F](/claim/clm_F4D24DFDC05F.md)
- 2020-09-30 to 2021-03-31 | money | quarterly_research_and_development | 3,390,000,000 United States dollar | superseded | [clm_601363BB78C5](/claim/clm_601363BB78C5.md)
- 2020-09-30 to 2021-03-31 | money | quarterly_revenue | 12,551,000,000 United States dollar | superseded | [clm_5C1E46793168](/claim/clm_5C1E46793168.md)
- 2020-09-30 to 2020-12-31 | money | total_assets | 89,800,000,000 United States dollar | superseded | [clm_B8D35EEE2364](/claim/clm_B8D35EEE2364.md)
- 2020-09-30 to 2020-12-31 | money | total_equity | 29,186,000,000 United States dollar | superseded | [clm_2214A1ACEDDD](/claim/clm_2214A1ACEDDD.md)
- 2020-10-31 to 2021-01-31 | money | shares_outstanding | 2,530,034,437 shares | superseded | [clm_19A0DB5C39B2](/claim/clm_19A0DB5C39B2.md)
- 2020-12-31 to 2021-03-31 | money | cash_and_equivalents | 8,062,000,000 United States dollar | superseded | [clm_3479D27E9553](/claim/clm_3479D27E9553.md)
- 2020-12-31 to 2021-12-31 | money | net_income | 7,067,000,000 United States dollar | superseded | [clm_F81DAFAD73AE](/claim/clm_F81DAFAD73AE.md)
- 2020-12-31 to 2021-12-31 | money | research_and_development | 13,558,000,000 United States dollar | superseded | [clm_6003F5963D12](/claim/clm_6003F5963D12.md)
- 2020-12-31 to 2021-12-31 | money | revenue | 47,994,000,000 United States dollar | superseded | [clm_F41E55DA096F](/claim/clm_F41E55DA096F.md)
- 2020-12-31 to 2021-03-31 | money | total_assets | 91,588,000,000 United States dollar | superseded | [clm_2D92122CFA57](/claim/clm_2D92122CFA57.md)
- 2020-12-31 to 2021-03-31 | money | total_equity | 25,317,000,000 United States dollar | superseded | [clm_B923437A977E](/claim/clm_B923437A977E.md)

## 2021

- 2021-01-31 to 2021-04-30 | money | shares_outstanding | 2,530,315,668 shares | superseded | [clm_DB50492A0D5C](/claim/clm_DB50492A0D5C.md)
- 2021-03-31 to 2021-06-30 | money | cash_and_equivalents | 6,981,000,000 United States dollar | superseded | [clm_2DA98D07113A](/claim/clm_2DA98D07113A.md)
- 2021-03-31 to 2021-06-30 | money | quarterly_net_income | 3,179,000,000 United States dollar | superseded | [clm_64B45488298B](/claim/clm_64B45488298B.md)
- 2021-03-31 to 2021-06-30 | money | quarterly_research_and_development | 2,465,000,000 United States dollar | superseded | [clm_602E83B5A23B](/claim/clm_602E83B5A23B.md)
- 2021-03-31 to 2021-06-30 | money | quarterly_revenue | 12,080,000,000 United States dollar | superseded | [clm_2B42EB43141D](/claim/clm_2B42EB43141D.md)
- 2021-03-31 to 2021-06-30 | money | total_assets | 90,847,000,000 United States dollar | superseded | [clm_1D93C5758916](/claim/clm_1D93C5758916.md)
- 2021-03-31 to 2021-06-30 | money | total_equity | 26,945,000,000 United States dollar | superseded | [clm_29418B6878C2](/claim/clm_29418B6878C2.md)
- 2021-04-30 to 2021-07-31 | money | shares_outstanding | 2,532,058,364 shares | superseded | [clm_02F25E967F12](/claim/clm_02F25E967F12.md)
- 2021-06-30 to 2021-09-30 | money | cash_and_equivalents | 8,575,000,000 United States dollar | superseded | [clm_80ED88D5B228](/claim/clm_80ED88D5B228.md)
- 2021-06-30 to 2021-09-30 | money | quarterly_net_income | 1,545,000,000 United States dollar | superseded | [clm_0517E31C3FEB](/claim/clm_0517E31C3FEB.md)
- 2021-06-30 to 2021-09-30 | money | quarterly_research_and_development | 4,321,000,000 United States dollar | superseded | [clm_C3C0E7554FA8](/claim/clm_C3C0E7554FA8.md)
- 2021-06-30 to 2021-09-30 | money | quarterly_revenue | 11,402,000,000 United States dollar | superseded | [clm_C9956D0CFD23](/claim/clm_C9956D0CFD23.md)
- 2021-06-30 to 2021-09-30 | money | total_assets | 90,688,000,000 United States dollar | superseded | [clm_0AFE389E5C48](/claim/clm_0AFE389E5C48.md)
- 2021-06-30 to 2021-09-30 | money | total_equity | 33,294,000,000 United States dollar | superseded | [clm_6520ACD0ED9A](/claim/clm_6520ACD0ED9A.md)
- 2021-07-31 to 2021-10-31 | money | shares_outstanding | 2,531,374,696 shares | superseded | [clm_7D9AD895C751](/claim/clm_7D9AD895C751.md)
- 2021-09-30 to 2021-12-31 | money | cash_and_equivalents | 10,016,000,000 United States dollar | superseded | [clm_3A29303F7FB7](/claim/clm_3A29303F7FB7.md)
- 2021-09-30 to 2022-03-31 | money | quarterly_net_income | 4,567,000,000 United States dollar | superseded | [clm_7124FBE763AC](/claim/clm_7124FBE763AC.md)
- 2021-09-30 to 2022-03-31 | money | quarterly_research_and_development | 2,445,000,000 United States dollar | superseded | [clm_6271F68058A2](/claim/clm_6271F68058A2.md)
- 2021-09-30 to 2022-03-31 | money | quarterly_revenue | 13,154,000,000 United States dollar | superseded | [clm_B112868B77BC](/claim/clm_B112868B77BC.md)
- 2021-09-30 to 2021-12-31 | money | total_assets | 93,494,000,000 United States dollar | superseded | [clm_8FBD1A9DB37D](/claim/clm_8FBD1A9DB37D.md)
- 2021-09-30 to 2021-12-31 | money | total_equity | 35,794,000,000 United States dollar | superseded | [clm_7FAB128C3F5D](/claim/clm_7FAB128C3F5D.md)
- 2021-10-31 to 2022-01-31 | money | shares_outstanding | 2,525,943,936 shares | superseded | [clm_034CAAEA4834](/claim/clm_034CAAEA4834.md)
- 2021-12-31 to 2022-03-31 | money | cash_and_equivalents | 8,096,000,000 United States dollar | superseded | [clm_230B3C47EC80](/claim/clm_230B3C47EC80.md)
- 2021-12-31 to 2022-12-31 | money | net_income | 13,049,000,000 United States dollar | superseded | [clm_D12FFF001055](/claim/clm_D12FFF001055.md)
- 2021-12-31 to 2022-12-31 | money | research_and_development | 12,245,000,000 United States dollar | superseded | [clm_52D1E12C9A04](/claim/clm_52D1E12C9A04.md)
- 2021-12-31 to 2022-12-31 | money | revenue | 48,704,000,000 United States dollar | superseded | [clm_1B82FCD1E106](/claim/clm_1B82FCD1E106.md)
- 2021-12-31 to 2022-03-31 | money | total_assets | 105,694,000,000 United States dollar | superseded | [clm_0ED12C79C31B](/claim/clm_0ED12C79C31B.md)
- 2021-12-31 to 2022-03-31 | money | total_equity | 38,184,000,000 United States dollar | superseded | [clm_0FA531F72A09](/claim/clm_0FA531F72A09.md)

## 2022

- 2022-01-31 to 2022-04-30 | money | shares_outstanding | 2,527,733,606 shares | superseded | [clm_A990AD910616](/claim/clm_A990AD910616.md)
- 2022-03-31 to 2022-06-30 | money | cash_and_equivalents | 8,556,000,000 United States dollar | superseded | [clm_F618911BB8FA](/claim/clm_F618911BB8FA.md)
- 2022-03-31 to 2022-06-30 | money | quarterly_net_income | 4,310,000,000 United States dollar | superseded | [clm_F9B19A8CB34A](/claim/clm_F9B19A8CB34A.md)
- 2022-03-31 to 2022-06-30 | money | quarterly_research_and_development | 2,576,000,000 United States dollar | superseded | [clm_0B9FE3DC3835](/claim/clm_0B9FE3DC3835.md)
- 2022-03-31 to 2022-06-30 | money | quarterly_revenue | 15,901,000,000 United States dollar | superseded | [clm_7ADB25B68A37](/claim/clm_7ADB25B68A37.md)
- 2022-03-31 to 2022-06-30 | money | total_assets | 106,668,000,000 United States dollar | superseded | [clm_4630F75144F2](/claim/clm_4630F75144F2.md)
- 2022-03-31 to 2022-06-30 | money | total_equity | 40,883,000,000 United States dollar | superseded | [clm_1B94B2C3A373](/claim/clm_1B94B2C3A373.md)
- 2022-04-30 to 2022-07-31 | money | shares_outstanding | 2,528,805,025 shares | superseded | [clm_005E05AF6D5A](/claim/clm_005E05AF6D5A.md)
- 2022-06-30 to 2022-09-30 | money | cash_and_equivalents | 9,675,000,000 United States dollar | superseded | [clm_7A280FC574C3](/claim/clm_7A280FC574C3.md)
- 2022-06-30 to 2022-09-30 | money | quarterly_net_income | 3,944,000,000 United States dollar | superseded | [clm_83A31C592A58](/claim/clm_83A31C592A58.md)
- 2022-06-30 to 2022-09-30 | money | quarterly_research_and_development | 2,798,000,000 United States dollar | superseded | [clm_604E84C45015](/claim/clm_604E84C45015.md)
- 2022-06-30 to 2022-09-30 | money | quarterly_revenue | 14,593,000,000 United States dollar | superseded | [clm_C37B63E56958](/claim/clm_C37B63E56958.md)
- 2022-06-30 to 2022-09-30 | money | total_assets | 107,095,000,000 United States dollar | superseded | [clm_B3973D6129B8](/claim/clm_B3973D6129B8.md)
- 2022-06-30 to 2022-09-30 | money | total_equity | 43,243,000,000 United States dollar | superseded | [clm_1E7926206718](/claim/clm_1E7926206718.md)
- 2022-07-31 to 2022-10-31 | money | shares_outstanding | 2,533,279,845 shares | superseded | [clm_5509A8889DE0](/claim/clm_5509A8889DE0.md)
- 2022-09-30 to 2022-12-31 | money | cash_and_equivalents | 11,145,000,000 United States dollar | superseded | [clm_96DAE1AA412B](/claim/clm_96DAE1AA412B.md)
- 2022-09-30 to 2023-03-31 | money | quarterly_net_income | 3,248,000,000 United States dollar | superseded | [clm_1C94927C303E](/claim/clm_1C94927C303E.md)
- 2022-09-30 to 2023-03-31 | money | quarterly_research_and_development | 4,399,000,000 United States dollar | superseded | [clm_2E6751788C0B](/claim/clm_2E6751788C0B.md)
- 2022-09-30 to 2023-03-31 | money | quarterly_revenue | 14,959,000,000 United States dollar | superseded | [clm_0A8F928CFC04](/claim/clm_0A8F928CFC04.md)
- 2022-09-30 to 2022-12-31 | money | total_assets | 107,081,000,000 United States dollar | superseded | [clm_39CF5C3FBCD8](/claim/clm_39CF5C3FBCD8.md)
- 2022-09-30 to 2022-12-31 | money | total_equity | 44,458,000,000 United States dollar | superseded | [clm_6012CA07BC66](/claim/clm_6012CA07BC66.md)
- 2022-10-31 to 2023-01-31 | money | shares_outstanding | 2,535,395,974 shares | superseded | [clm_ACD78053B586](/claim/clm_ACD78053B586.md)
- 2022-12-31 to 2023-03-31 | money | cash_and_equivalents | 12,694,000,000 United States dollar | superseded | [clm_3F973E2A6316](/claim/clm_3F973E2A6316.md)
- 2022-12-31 to 2023-12-31 | money | net_income | 14,519,000,000 United States dollar | superseded | [clm_6570159626A7](/claim/clm_6570159626A7.md)
- 2022-12-31 to 2023-12-31 | money | research_and_development | 13,548,000,000 United States dollar | superseded | [clm_072FE6304876](/claim/clm_072FE6304876.md)
- 2022-12-31 to 2023-12-31 | money | revenue | 59,283,000,000 United States dollar | superseded | [clm_B88AE5A69CF1](/claim/clm_B88AE5A69CF1.md)
- 2022-12-31 to 2023-03-31 | money | total_assets | 109,160,000,000 United States dollar | superseded | [clm_5F726FFCF0E7](/claim/clm_5F726FFCF0E7.md)
- 2022-12-31 to 2023-03-31 | money | total_equity | 45,991,000,000 United States dollar | superseded | [clm_D324B5015E5C](/claim/clm_D324B5015E5C.md)

## 2023

- 2023-01-31 to 2023-04-30 | money | shares_outstanding | 2,538,592,467 shares | superseded | [clm_0DECBB030961](/claim/clm_0DECBB030961.md)
- 2023-03-31 to 2023-06-30 | money | cash_and_equivalents | 9,707,000,000 United States dollar | superseded | [clm_C41F804AD4A0](/claim/clm_C41F804AD4A0.md)
- 2023-03-31 to 2023-06-30 | money | quarterly_net_income | 2,821,000,000 United States dollar | superseded | [clm_E5378AE4C74A](/claim/clm_E5378AE4C74A.md)
- 2023-03-31 to 2023-06-30 | money | quarterly_research_and_development | 4,276,000,000 United States dollar | superseded | [clm_FD249791F8E3](/claim/clm_FD249791F8E3.md)
- 2023-03-31 to 2023-06-30 | money | quarterly_revenue | 14,487,000,000 United States dollar | superseded | [clm_353C9EC1DE74](/claim/clm_353C9EC1DE74.md)
- 2023-03-31 to 2023-06-30 | money | total_assets | 107,796,000,000 United States dollar | superseded | [clm_89BCC3ECADC9](/claim/clm_89BCC3ECADC9.md)
- 2023-03-31 to 2023-06-30 | money | total_equity | 46,834,000,000 United States dollar | superseded | [clm_09E404D0868B](/claim/clm_09E404D0868B.md)
- 2023-04-30 to 2023-07-31 | money | shares_outstanding | 2,537,435,954 shares | superseded | [clm_F79642CF67D5](/claim/clm_F79642CF67D5.md)
- 2023-06-30 to 2023-09-30 | money | cash_and_equivalents | 5,660,000,000 United States dollar | superseded | [clm_491D9D1C284F](/claim/clm_491D9D1C284F.md)
- 2023-06-30 to 2023-09-30 | money | quarterly_net_income | -5,975,000,000 United States dollar | superseded | [clm_808DE613CD03](/claim/clm_808DE613CD03.md)
- 2023-06-30 to 2023-09-30 | money | quarterly_research_and_development | 13,321,000,000 United States dollar | superseded | [clm_2AC71CAE212F](/claim/clm_2AC71CAE212F.md)
- 2023-06-30 to 2023-09-30 | money | quarterly_revenue | 15,035,000,000 United States dollar | superseded | [clm_CD754CF29134](/claim/clm_CD754CF29134.md)
- 2023-06-30 to 2023-09-30 | money | total_assets | 104,469,000,000 United States dollar | superseded | [clm_1A32EEA6D6EC](/claim/clm_1A32EEA6D6EC.md)
- 2023-06-30 to 2023-09-30 | money | total_equity | 38,693,000,000 United States dollar | superseded | [clm_24E9A9145867](/claim/clm_24E9A9145867.md)
- 2023-07-31 to 2023-10-31 | money | shares_outstanding | 2,537,521,169 shares | superseded | [clm_694106887509](/claim/clm_694106887509.md)
- 2023-09-30 to 2023-12-31 | money | cash_and_equivalents | 8,605,000,000 United States dollar | superseded | [clm_C7767A31CAA9](/claim/clm_C7767A31CAA9.md)
- 2023-09-30 to 2024-03-31 | money | quarterly_net_income | 4,745,000,000 United States dollar | superseded | [clm_DBF24049DC48](/claim/clm_DBF24049DC48.md)
- 2023-09-30 to 2024-03-31 | money | quarterly_research_and_development | 3,307,000,000 United States dollar | superseded | [clm_85D17F8D14B8](/claim/clm_85D17F8D14B8.md)
- 2023-09-30 to 2024-03-31 | money | quarterly_revenue | 15,962,000,000 United States dollar | superseded | [clm_65DECC611D27](/claim/clm_65DECC611D27.md)
- 2023-09-30 to 2023-12-31 | money | total_assets | 106,727,000,000 United States dollar | superseded | [clm_ED1497B9B9A8](/claim/clm_ED1497B9B9A8.md)
- 2023-09-30 to 2023-12-31 | money | total_equity | 41,246,000,000 United States dollar | superseded | [clm_EC64212C5C0B](/claim/clm_EC64212C5C0B.md)
- 2023-10-31 to 2024-01-31 | money | shares_outstanding | 2,534,023,084 shares | superseded | [clm_88B7C84F347E](/claim/clm_88B7C84F347E.md)
- 2023-12-31 to 2024-03-31 | money | cash_and_equivalents | 6,841,000,000 United States dollar | superseded | [clm_8B721020A859](/claim/clm_8B721020A859.md)
- 2023-12-31 to 2024-12-31 | money | net_income | 365,000,000 United States dollar | superseded | [clm_00E79EEE61A1](/claim/clm_00E79EEE61A1.md)
- 2023-12-31 to 2024-12-31 | money | research_and_development | 30,531,000,000 United States dollar | superseded | [clm_9F3A2514948A](/claim/clm_9F3A2514948A.md)
- 2023-12-31 to 2024-12-31 | money | revenue | 60,115,000,000 United States dollar | superseded | [clm_ABA0DDBCEC64](/claim/clm_ABA0DDBCEC64.md)
- 2023-12-31 to 2024-03-31 | money | total_assets | 106,675,000,000 United States dollar | superseded | [clm_26E68DAA6E4F](/claim/clm_26E68DAA6E4F.md)
- 2023-12-31 to 2024-03-31 | money | total_equity | 37,581,000,000 United States dollar | superseded | [clm_D509213C3811](/claim/clm_D509213C3811.md)

## 2024

- 2024-01-31 to 2024-04-30 | money | shares_outstanding | 2,532,643,872 shares | superseded | [clm_95A1CC25AF02](/claim/clm_95A1CC25AF02.md)
- 2024-03-31 to 2024-06-30 | money | cash_and_equivalents | 5,579,000,000 United States dollar | superseded | [clm_61D652C2AA20](/claim/clm_61D652C2AA20.md)
- 2024-03-31 to 2024-06-30 | money | quarterly_net_income | 4,762,000,000 United States dollar | superseded | [clm_19ED07FEF676](/claim/clm_19ED07FEF676.md)
- 2024-03-31 to 2024-06-30 | money | quarterly_research_and_development | 3,992,000,000 United States dollar | superseded | [clm_DD2E2358C2C5](/claim/clm_DD2E2358C2C5.md)
- 2024-03-31 to 2024-06-30 | money | quarterly_revenue | 15,775,000,000 United States dollar | superseded | [clm_8611BE831E10](/claim/clm_8611BE831E10.md)
- 2024-03-31 to 2024-06-30 | money | total_assets | 105,849,000,000 United States dollar | superseded | [clm_BDB2E27B4E60](/claim/clm_BDB2E27B4E60.md)
- 2024-03-31 to 2024-06-30 | money | total_equity | 40,364,000,000 United States dollar | superseded | [clm_866522253978](/claim/clm_866522253978.md)
- 2024-04-30 to 2024-07-31 | money | shares_outstanding | 2,532,806,307 shares | superseded | [clm_84C234FF7850](/claim/clm_84C234FF7850.md)
- 2024-06-30 to 2024-09-30 | money | cash_and_equivalents | 11,304,000,000 United States dollar | superseded | [clm_53A19AADAE82](/claim/clm_53A19AADAE82.md)
- 2024-06-30 to 2024-09-30 | money | quarterly_net_income | 5,455,000,000 United States dollar | superseded | [clm_9D2EE4822EFB](/claim/clm_9D2EE4822EFB.md)
- 2024-06-30 to 2024-09-30 | money | quarterly_research_and_development | 3,500,000,000 United States dollar | superseded | [clm_64E8125CC2B5](/claim/clm_64E8125CC2B5.md)
- 2024-06-30 to 2024-09-30 | money | quarterly_revenue | 16,112,000,000 United States dollar | superseded | [clm_CA3727C7A4E6](/claim/clm_CA3727C7A4E6.md)
- 2024-06-30 to 2024-09-30 | money | total_assets | 112,630,000,000 United States dollar | superseded | [clm_0F3839AEFD94](/claim/clm_0F3839AEFD94.md)
- 2024-06-30 to 2024-09-30 | money | total_equity | 43,582,000,000 United States dollar | superseded | [clm_34EB6E01BD4E](/claim/clm_34EB6E01BD4E.md)
- 2024-07-31 to 2024-10-31 | money | shares_outstanding | 2,534,809,312 shares | superseded | [clm_CA8B975E05B4](/claim/clm_CA8B975E05B4.md)
- 2024-09-30 to 2024-12-31 | money | cash_and_equivalents | 14,593,000,000 United States dollar | superseded | [clm_32776455365F](/claim/clm_32776455365F.md)
- 2024-09-30 to 2025-03-31 | money | quarterly_net_income | 3,157,000,000 United States dollar | superseded | [clm_7D92F6A5B925](/claim/clm_7D92F6A5B925.md)
- 2024-09-30 to 2025-03-31 | money | quarterly_research_and_development | 5,862,000,000 United States dollar | superseded | [clm_EF9F40E4249B](/claim/clm_EF9F40E4249B.md)
- 2024-09-30 to 2025-03-31 | money | quarterly_revenue | 16,657,000,000 United States dollar | superseded | [clm_81BBE85997B1](/claim/clm_81BBE85997B1.md)
- 2024-09-30 to 2024-12-31 | money | total_assets | 117,532,000,000 United States dollar | superseded | [clm_A6EF3EF9F17B](/claim/clm_A6EF3EF9F17B.md)
- 2024-09-30 to 2024-12-31 | money | total_equity | 44,502,000,000 United States dollar | superseded | [clm_452ECF596A5A](/claim/clm_452ECF596A5A.md)
- 2024-10-31 to 2025-01-31 | money | shares_outstanding | 2,529,635,645 shares | superseded | [clm_EF29FF74A1DA](/claim/clm_EF29FF74A1DA.md)
- 2024-12-31 to 2025-03-31 | money | cash_and_equivalents | 13,242,000,000 United States dollar | superseded | [clm_836E3FCB29EF](/claim/clm_836E3FCB29EF.md)
- 2024-12-31 to 2025-12-31 | money | net_income | 17,117,000,000 United States dollar | superseded | [clm_C6B723CD22D3](/claim/clm_C6B723CD22D3.md)
- 2024-12-31 to 2025-12-31 | money | research_and_development | 17,938,000,000 United States dollar | superseded | [clm_B017880F2FAE](/claim/clm_B017880F2FAE.md)
- 2024-12-31 to 2025-12-31 | money | revenue | 64,168,000,000 United States dollar | superseded | [clm_B00A59ED1285](/claim/clm_B00A59ED1285.md)
- 2024-12-31 to 2025-03-31 | money | total_assets | 117,106,000,000 United States dollar | superseded | [clm_10EEDDF5060A](/claim/clm_10EEDDF5060A.md)
- 2024-12-31 to 2025-03-31 | money | total_equity | 46,313,000,000 United States dollar | superseded | [clm_5998C6109ED8](/claim/clm_5998C6109ED8.md)

## 2025

- 2025-01-31 to 2025-04-30 | money | shares_outstanding | 2,526,036,240 shares | superseded | [clm_F14BC63CE196](/claim/clm_F14BC63CE196.md)
- 2025-03-31 to 2025-06-30 | money | cash_and_equivalents | 8,629,000,000 United States dollar | superseded | [clm_6E7A454B6848](/claim/clm_6E7A454B6848.md)
- 2025-03-31 to 2025-06-30 | money | quarterly_net_income | 5,079,000,000 United States dollar | superseded | [clm_D254D3EB3376](/claim/clm_D254D3EB3376.md)
- 2025-03-31 to 2025-06-30 | money | quarterly_research_and_development | 3,621,000,000 United States dollar | superseded | [clm_788ACEC11B0D](/claim/clm_788ACEC11B0D.md)
- 2025-03-31 to 2025-06-30 | money | quarterly_revenue | 15,529,000,000 United States dollar | superseded | [clm_9639B624984C](/claim/clm_9639B624984C.md)
- 2025-03-31 to 2025-06-30 | money | total_assets | 115,122,000,000 United States dollar | superseded | [clm_A6351EF8D62A](/claim/clm_A6351EF8D62A.md)
- 2025-03-31 to 2025-06-30 | money | total_equity | 48,335,000,000 United States dollar | superseded | [clm_2B02E20CD535](/claim/clm_2B02E20CD535.md)
- 2025-04-30 to 2025-07-31 | money | shares_outstanding | 2,511,031,253 shares | superseded | [clm_37C45B0F3389](/claim/clm_37C45B0F3389.md)
- 2025-06-30 to 2025-09-30 | money | cash_and_equivalents | 8,007,000,000 United States dollar | superseded | [clm_9989FAB3CB44](/claim/clm_9989FAB3CB44.md)
- 2025-06-30 to 2025-09-30 | money | quarterly_net_income | 4,427,000,000 United States dollar | superseded | [clm_CB2E2563DBAE](/claim/clm_CB2E2563DBAE.md)
- 2025-06-30 to 2025-09-30 | money | quarterly_research_and_development | 4,048,000,000 United States dollar | superseded | [clm_6E0F8CB5C8F7](/claim/clm_6E0F8CB5C8F7.md)
- 2025-06-30 to 2025-09-30 | money | quarterly_revenue | 15,806,000,000 United States dollar | superseded | [clm_A023A3BF80C0](/claim/clm_A023A3BF80C0.md)
- 2025-06-30 to 2025-09-30 | money | total_assets | 117,523,000,000 United States dollar | superseded | [clm_FF7386E5859A](/claim/clm_FF7386E5859A.md)
- 2025-06-30 to 2025-09-30 | money | total_equity | 48,993,000,000 United States dollar | superseded | [clm_CD7198CC2749](/claim/clm_CD7198CC2749.md)
- 2025-07-31 to 2025-10-31 | money | shares_outstanding | 2,497,783,211 shares | superseded | [clm_DF652357EB7C](/claim/clm_DF652357EB7C.md)
- 2025-09-30 to 2025-12-31 | money | cash_and_equivalents | 18,169,000,000 United States dollar | superseded | [clm_C86D1A2441BE](/claim/clm_C86D1A2441BE.md)
- 2025-09-30 to 2026-03-31 | money | quarterly_net_income | 5,785,000,000 United States dollar | superseded | [clm_44C6DC623BB5](/claim/clm_44C6DC623BB5.md)
- 2025-09-30 to 2026-03-31 | money | quarterly_research_and_development | 4,234,000,000 United States dollar | superseded | [clm_E7C205B81C1E](/claim/clm_E7C205B81C1E.md)
- 2025-09-30 to 2026-03-31 | money | quarterly_revenue | 17,276,000,000 United States dollar | superseded | [clm_86C0BCF4E479](/claim/clm_86C0BCF4E479.md)
- 2025-09-30 to 2025-12-31 | money | total_assets | 129,546,000,000 United States dollar | superseded | [clm_7F62C5E7C6D5](/claim/clm_7F62C5E7C6D5.md)
- 2025-09-30 to 2025-12-31 | money | total_equity | 51,850,000,000 United States dollar | superseded | [clm_BDAEC6471AF2](/claim/clm_BDAEC6471AF2.md)
- 2025-10-31 to 2026-01-31 | money | shares_outstanding | 2,482,022,536 shares | superseded | [clm_216265EA32A0](/claim/clm_216265EA32A0.md)
- 2025-12-31 to 2026-03-31 | money | cash_and_equivalents | 14,565,000,000 United States dollar | superseded | [clm_DB573F068746](/claim/clm_DB573F068746.md)
- 2025-12-31 | money | net_income | 18,254,000,000 United States dollar | valid | [clm_23107EF0C145](/claim/clm_23107EF0C145.md)
- 2025-12-31 | money | research_and_development | 15,789,000,000 United States dollar | valid | [clm_062934F11209](/claim/clm_062934F11209.md)
- 2025-12-31 | money | revenue | 65,011,000,000 United States dollar | valid | [clm_E778C75FD821](/claim/clm_E778C75FD821.md)
- 2025-12-31 to 2026-03-31 | money | total_assets | 136,866,000,000 United States dollar | superseded | [clm_4A91E3E067AC](/claim/clm_4A91E3E067AC.md)
- 2025-12-31 to 2026-03-31 | money | total_equity | 52,606,000,000 United States dollar | superseded | [clm_4011DB45C7C0](/claim/clm_4011DB45C7C0.md)

## 2026

- 2026-01-31 to 2026-04-30 | money | shares_outstanding | 2,472,392,003 shares | superseded | [clm_816D1195758B](/claim/clm_816D1195758B.md)
- 2026-03-31 to 2026-06-30 | money | cash_and_equivalents | 5,327,000,000 United States dollar | superseded | [clm_4EF7F384C3E5](/claim/clm_4EF7F384C3E5.md)
- 2026-03-31 to 2026-06-30 | money | quarterly_net_income | -4,240,000,000 United States dollar | superseded | [clm_052408C1DABC](/claim/clm_052408C1DABC.md)
- 2026-03-31 to 2026-06-30 | money | quarterly_research_and_development | 12,592,000,000 United States dollar | superseded | [clm_CC42DDED77FE](/claim/clm_CC42DDED77FE.md)
- 2026-03-31 to 2026-06-30 | money | quarterly_revenue | 16,286,000,000 United States dollar | superseded | [clm_A5059DD1C3C6](/claim/clm_A5059DD1C3C6.md)
- 2026-03-31 to 2026-06-30 | money | total_assets | 128,685,000,000 United States dollar | superseded | [clm_6DF831C7A399](/claim/clm_6DF831C7A399.md)
- 2026-03-31 to 2026-06-30 | money | total_equity | 45,878,000,000 United States dollar | superseded | [clm_2EAD708A2D4D](/claim/clm_2EAD708A2D4D.md)
- 2026-04-30 to 2026-07-31 | money | shares_outstanding | 2,469,824,415 shares | superseded | [clm_3D54FBDF161B](/claim/clm_3D54FBDF161B.md)
- 2026-06-30 to 2026-09-30 | money | cash_and_equivalents | 6,849,000,000 United States dollar | superseded | [clm_9B76B2EBE76B](/claim/clm_9B76B2EBE76B.md)
- 2026-06-30 to 2026-09-30 | money | quarterly_net_income | -1,335,000,000 United States dollar | superseded | [clm_3CFDEE3E892F](/claim/clm_3CFDEE3E892F.md)
- 2026-06-30 to 2026-09-30 | money | quarterly_research_and_development | 9,741,000,000 United States dollar | superseded | [clm_6963A9FE29D9](/claim/clm_6963A9FE29D9.md)
- 2026-06-30 to 2026-09-30 | money | quarterly_revenue | 16,607,000,000 United States dollar | superseded | [clm_59257F264468](/claim/clm_59257F264468.md)
- 2026-06-30 to 2026-09-30 | money | total_assets | 129,802,000,000 United States dollar | superseded | [clm_1D21FB857339](/claim/clm_1D21FB857339.md)
- 2026-06-30 to 2026-09-30 | money | total_equity | 41,933,000,000 United States dollar | superseded | [clm_56023EED76B1](/claim/clm_56023EED76B1.md)
- 2026-07-31 to 2026-10-31 | money | shares_outstanding | 2,467,171,638 shares | superseded | [clm_551368D9DFD9](/claim/clm_551368D9DFD9.md)
- 2026-09-30 | money | cash_and_equivalents | 9,550,000,000 United States dollar | valid | [clm_5760FE8DF5CC](/claim/clm_5760FE8DF5CC.md)
- 2026-09-30 | money | quarterly_net_income | 5,065,000,000 United States dollar | valid | [clm_BE2114005849](/claim/clm_BE2114005849.md)
- 2026-09-30 | money | quarterly_research_and_development | 4,537,000,000 United States dollar | valid | [clm_8D15B1B2A78D](/claim/clm_8D15B1B2A78D.md)
- 2026-09-30 | money | quarterly_revenue | 18,085,000,000 United States dollar | valid | [clm_D93F566AE261](/claim/clm_D93F566AE261.md)
- 2026-09-30 | money | total_assets | 132,773,000,000 United States dollar | valid | [clm_700C48638C17](/claim/clm_700C48638C17.md)
- 2026-09-30 | money | total_equity | 44,893,000,000 United States dollar | valid | [clm_23DBC8C334E1](/claim/clm_23DBC8C334E1.md)
- 2026-10-31 | money | shares_outstanding | 2,465,245,688 shares | valid | [clm_B0FE93A73A8D](/claim/clm_B0FE93A73A8D.md)

## undated

- undated | other | website | https://www.merck.com | unverified | [clm_500A250794EC](/claim/clm_500A250794EC.md)
- undated | other | cik | 0000310158 | valid | [clm_866F817FFD7C](/claim/clm_866F817FFD7C.md)
- undated | other | fiscal_year_end | 12-31 | valid | [clm_D6EE533D837B](/claim/clm_D6EE533D837B.md)
- undated | other | headquarters | Rahway | valid | [clm_BFFD023A5D40](/claim/clm_BFFD023A5D40.md)
- undated | other | listed_on | NYSE | valid | [clm_88B4EFBC615C](/claim/clm_88B4EFBC615C.md)
- undated | other | sic_industry | Pharmaceutical Preparations (2834) | valid | [clm_7424130E993D](/claim/clm_7424130E993D.md)
- undated | other | state_of_incorporation | NJ | valid | [clm_611073235D86](/claim/clm_611073235D86.md)
- undated | other | ticker | MRK | valid | [clm_37834FC2D131](/claim/clm_37834FC2D131.md)

---

AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.